These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 3377641)
1. Dopamine metabolism and disposition in schizophrenic patients. Studies using debrisoquin. Maas JW; Contreras SA; Seleshi E; Bowden CL Arch Gen Psychiatry; 1988 Jun; 45(6):553-9. PubMed ID: 3377641 [TBL] [Abstract][Full Text] [Related]
2. Studies of catecholamine metabolism in schizophrenia/psychosis--I. Maas JW; Contreras SA; Miller AL; Berman N; Bowden CL; Javors MA; Seleshi E; Weintraub S Neuropsychopharmacology; 1993 Feb; 8(2):97-109. PubMed ID: 8471132 [TBL] [Abstract][Full Text] [Related]
3. A new approach to biochemical evaluation of brain dopamine metabolism. Kopin IJ; White JH; Bankiewicz K Cell Mol Neurobiol; 1988 Jun; 8(2):171-9. PubMed ID: 3044592 [TBL] [Abstract][Full Text] [Related]
4. Acute effects of neuroleptics on unmedicated schizophrenic patients and controls. Miller AL; Maas JW; Contreras S; Seleshi E; True JE; Bowden C; Castiglioni J Biol Psychiatry; 1993 Aug; 34(3):178-87. PubMed ID: 8104509 [TBL] [Abstract][Full Text] [Related]
5. Assessment of brain dopamine metabolism from plasma HVA and MHPG during debrisoquin treatment: validation in monkeys treated with MPTP. Kopin IJ; Bankiewicz KS; Harvey-White J Neuropsychopharmacology; 1988 May; 1(2):119-25. PubMed ID: 3266957 [TBL] [Abstract][Full Text] [Related]
6. Plasma homovanillic acid as an index of brain dopamine metabolism: enhancement with debrisoquin. Sternberg DE; Heninger GR; Roth RH Life Sci; 1983 May; 32(21):2447-52. PubMed ID: 6855448 [TBL] [Abstract][Full Text] [Related]
7. Assessment of the central dopaminergic index of plasma HVA in schizophrenia. Amin F; Davidson M; Kahn RS; Schmeidler J; Stern R; Knott PJ; Apter S Schizophr Bull; 1995; 21(1):53-66. PubMed ID: 7770741 [TBL] [Abstract][Full Text] [Related]
8. Studies of catecholamine metabolism in schizophrenia/psychosis--II. Maas JW; Contreras SA; Miller AL; Berman N; Bowden CL; Javors MA; Seleshi E; Weintraub SE Neuropsychopharmacology; 1993 Feb; 8(2):111-6. PubMed ID: 8471122 [TBL] [Abstract][Full Text] [Related]
9. Effect of MPTP-induced parkinsonism in monkeys on the urinary excretion of HVA and MHPG during debrisoquin administration. Kopin IJ; Bankiewicz K; Harvey-White J Life Sci; 1988; 43(2):133-41. PubMed ID: 3260652 [TBL] [Abstract][Full Text] [Related]
10. Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma. Hovevey-Sion D; Kopin IJ; Stull RW; Goldstein DS Neuropharmacology; 1989 Aug; 28(8):791-7. PubMed ID: 2506486 [TBL] [Abstract][Full Text] [Related]
11. Effects of debrisoquin on CSF and plasma HVA concentrations in man. Maas JW; Contreras SA; Bowden CL; Weintraub SE Life Sci; 1985 Jun; 36(22):2163-70. PubMed ID: 3999921 [TBL] [Abstract][Full Text] [Related]
12. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209 [TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Pickar D; Breier A; Hsiao JK; Doran AR; Wolkowitz OM; Pato CN; Konicki PE; Potter WZ Arch Gen Psychiatry; 1990 Jul; 47(7):641-8. PubMed ID: 1694425 [TBL] [Abstract][Full Text] [Related]
14. Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine. Nikisch G; Baumann P; Kiessling B; Reinert M; Wiedemann G; Kehr J; Mathé AA; Piel M; Roesch F; Weisser H; Schneider P; Hertel A J Psychiatr Res; 2010 Sep; 44(12):754-9. PubMed ID: 20176367 [TBL] [Abstract][Full Text] [Related]
15. The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients. Konicki PE; Owen RR; Litman RE; Pickar D Life Sci; 1991; 48(14):1411-6. PubMed ID: 2008157 [TBL] [Abstract][Full Text] [Related]
16. Assessment of central dopaminergic function using plasma-free homovanillic acid after debrisoquin administration. Riddle MA; Leckman JF; Cohen DJ; Anderson M; Ort SI; Caruso KA; Shaywitz BA J Neural Transm; 1986; 67(1-2):31-43. PubMed ID: 3465864 [TBL] [Abstract][Full Text] [Related]
17. Neurochemical variables in delusional depression. Lykouras E; Markianos M; Malliaras D; Stefanis C Am J Psychiatry; 1988 Feb; 145(2):214-7. PubMed ID: 2449085 [TBL] [Abstract][Full Text] [Related]
18. Relationship between plasma and cerebrospinal fluid norepinephrine and dopamine metabolites in a nonhuman primate. Greene KA; Faull KF J Neurochem; 1989 Oct; 53(4):1007-13. PubMed ID: 2769251 [TBL] [Abstract][Full Text] [Related]
19. Monoamine related functional gene variants and relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Jönsson EG; Bah J; Melke J; Abou Jamra R; Schumacher J; Westberg L; Ivo R; Cichon S; Propping P; Nöthen MM; Eriksson E; Sedvall GC BMC Psychiatry; 2004 Mar; 4():4. PubMed ID: 15102340 [TBL] [Abstract][Full Text] [Related]
20. [Concentrations of monoamines and monoamine metabolites in cerebrospinal fluid determined by high-performance liquid chromatography with electrochemical detection]. Yoshino K No To Shinkei; 1982 Nov; 34(11):1099-106. PubMed ID: 6186264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]